key: cord-0904825-s2ohm6k4
authors: Herta, Toni; Berg, Thomas
title: COVID‐19 and the liver – Lessons learned
date: 2021-06-21
journal: Liver Int
DOI: 10.1111/liv.14854
sha: e0c00bc1ae5ac13930b0e1ade547d8997b002f0d
doc_id: 904825
cord_uid: s2ohm6k4

Liver involvement, indicated by elevated liver function test results, is common in hospitalized patients with coronavirus disease 2019 (COVID‐19) and has been linked to disease severity and outcome. A dual pattern of elevated liver function tests can be observed especially in patients with severe or critical COVID‐19, characterized by an increase in aminotransferases early in the course of this disease, followed by an increase in cholestasis‐associated biochemistry markers at later stages. This dual pattern is associated with inflammatory response markers and poor outcome. Current notions on the mechanisms of liver injury in COVID‐19 include direct cytopathic effects of the virus on hepatocytes and cholangiocytes, ischemic and hypoxic liver damage, drug‐induced liver injury, activation of hepatic immune cells by excess cytokine production and exacerbation of pre‐existing liver disease. Patients with obesity‐related non‐alcoholic fatty liver disease and, in particular, patients with cirrhosis are at high risk of liver injury and a fatal outcome from COVID‐19. In contrast, individuals receiving stable immunosuppressive medication for autoimmune liver diseases or during long‐term follow‐up after liver transplantation do not have a higher case‐to‐infection ratio and have a fairly favourable outcome. The present review describes the epidemiology, characteristics and potential pathological mechanisms of COVID‐19‐related liver injury. Moreover, the influence of pre‐existing liver disease on the susceptibility and severity of liver injury in COVID‐19 are discussed.

Coronavirus disease 2019 (COVID-19) is a contagious, zoonotic respiratory infection caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). COVID-19 was first reported in December 2019 in a series of patients with severe pneumonia with a fatal outcome in certain cases, following exposure to the Huanan seafood market in Wuhan, Central China, 1 and has since spread worldwide with more than 37 million cases and 1 million deaths, as of October 2020. In addition to acute respiratory tract symptoms, abnormal liver function tests were observed in 14%-69% of patients, mostly identified by transient elevation of aminotransferases. [2] [3] [4] Liver injury from COVID-19 seems to mirror disease severity, as patients with severe COVID-19 are more likely to have elevated liver function tests 3, 5 and higher peaks of elevation 4,6 than those with milder disease. Whether these observations reflect direct SARS-CoV-2-mediated liver damage, secondary liver injury from systemic COVID-19 or more severe courses of COVID-19 in patients with pre-existing liver disease has not been clarified. The present review describes the epidemiology, characteristics and potential pathological mechanisms of COVID-19-related liver injury. Moreover, the influence of pre-existing liver disease on the susceptibility to, severity of and liver injury in COVID-19 are discussed.

Abnormal liver function tests in patients with COVID-19 were first reported in a cohort of 99 patients at Jinyiantan Hospital in Wuhan.

Nearly all patients (98%) presented with decreased albumin levels (mean 31.6 g/L, normal range 40-55 g/L). Alanine aminotransferase (ALAT) and aspartate aminotransferase (ASAT) levels were moderately elevated in 28% and 35% of patients respectively. One patient had severe liver damage (ALAT 7590 U/L and ASAT 1445 U/L).

Slightly elevated total bilirubin levels were less common (18% of the cases). 7 Twelve single-and multicentre studies in China with a total of 2264 included patients analysed aminotransferase levels in patients with COVID 19. 2 Aminotransferase levels were above the upper limit of normal (ULN) at least once in 14%-53% of the patients.

Interestingly, the proportion of patients with increased aminotransferase levels was higher in Wuhan, the epicentre of COVID-19, than outside Wuhan (21% vs 10%, P < .0001). 3, 8 The authors suggest that this could be because of exposure to higher doses of SARS-CoV-2 with more severe courses of COVID- 19 6 A study at Massachusetts General Hospital in the USA followed liver function tests in 60 patients with COVID-19 for a median of 9 days during hospitalization. Aminotransferases increased to >ULN in 93% of the patients, while AP and total bilirubin levels remained normal (AP) or were mildly elevated (total bilirubin) in most patients, consistent with hepatocellular injury. Aminotransferases were >5× ULN in 17% of the patients. In particular, ASAT was higher than ALAT at admission (46 vs 30 U/L) and for most of the hospital stay (P < .05). Peak ASAT levels were higher in patients requiring mechanical ventilation (P = .003) and correlated with the length of hospital stay (P = .03). 4 An interesting, dual pattern of liver damage was reported in a survey including 540 hospitalized patients with severe COVID-19 from Zaragoza, Northern Spain, in which 40.9% and 47.3% of the patients presented with elevated ASAT and GGT levels at admission respectively. There was a negative correlation between initial oxygen saturation and ASAT but not GGT (P <.001 and P =.944 respectively). A longitudinal analysis showed that the progression of GGT levels was positively correlated with inflammatory markers such as C-reactive protein (CRP) and strongly increased in non-survivors but not in survivors during hospitalization (P < .001). 9 The authors concluded that SARS-CoV-2 may have a dual effect on the liver, characterized by elevated aminotransferases on admission followed by a marked cholestasis in patients with a fatal outcome ( Figure 1 ). Median albumin levels were already lower on admission in non-survivors than in survivors (3 g/dL vs 3.4 g/dL, respectively, P < .001), and further decreased in these patients during hospitalization. 9 In conclusion, abnormal liver function tests are common in COVID-19, mainly in the form of transient increases in aminotransferases. The incidence is higher in patients with severe COVID-19 than in those with mild disease. Acute hepatitis is occasionally reported. In patients with severe COVID-19, initial liver injury is characterized by elevated aminotransferases followed by a cholestatic pattern, and a significant decrease in albumin later in the course of the disease. Studies of liver function tests in outpatients with COVID-19 are lacking.

• Liver involvement, characterized by elevated liver function tests, is common in hospitalized patients with COVID-19.

• Patients with severe or critical disease courses are more likely to have elevated liver function tests and higher peaks of elevation.

• The mechanism of elevation is probably multifactorial liver injury.

• Patients with obesity-related non-alcoholic fatty liver disease and, in particular, patients with advanced cirrhosis are at high risk of liver injury and a fatal outcome from COVID-19.

• Optimal treatment and compensation of chronic liver disease are critical to prevent severe courses of COVID-19 in these patients.

Reports on the mechanism of COVID-19-related liver injury are limited. However, several notions have been discussed ( Figure 2 ): (i) Direct SARS-CoV-2-induced cytopathic effects on hepatocytes and cholangiocytes. SARS-CoV-2 expresses a surface glycoprotein, called spike, on the viral envelope, which binds to the receptor angiotensin-converting enzyme 2 (ACE2) on human host cells and, thus, mediates viral entry into the host cell cytoplasm. 10 ACE2 is expressed in a variety of human tissues such as the lungs, heart, kidneys, pancreas, blood vessels, adipose tissue and liver. Singlecell RNA sequencing revealed marked enrichment of ACE2 expression in cholangiocytes but an average expression in hepatocytes that was 20 times lower (59.7% vs 2.6% of ACE2 positive cells). 11 Hepatic immune and stromal cells were ACE2 negative. Thus, it could be hypothesized that SARS-CoV-2 infects cholangiocytes but probably not hepatocytes. However, this notion is not supported by the cell tropism profile of SARS-CoV-2. Human Huh7 hepatocellular carcinoma cells are highly susceptible to SARS-CoV-2 infection. 12 Moreover, liver and cholangiocyte organoids derived from human pluripotent stem cells are permissive to SARS-CoV-2 infection as seen by high levels of viral RNA transcription after inoculation with a SARS-CoV-2 isolate. Infected hepatocytes and cholangiocytes showed marked pro-inflammatory chemokine induction and downregulation of metabolic markers. 13 Viral genomic RNA was identified in 3 of 4 samples of a series of post-mortem examinations of the livers of patients who died from severe COVID-19. 14 One possible explanation for the unexpected tropism of SARS-CoV-2 to hepatocytes could be its exceptionally strong binding affinity to ACE2 which could facilitate virus entry despite low ACE2 expression levels. 10, 12 Furthermore, as discussed below, hypoxia and pre-existing liver disease are thought to induce hepatocellular ACE2 expression and potentially increase hepatic susceptibility to SARS-CoV-2 infection. 15, 16 One study observed spike structures in the cytoplasm of hepatocytes of 2 COVID-19 cases with transmission electron microscopy. These structures were defined as coronavirus particles.

Affected hepatocytes exhibited potentially cytopathic lesions such as mitochondrial swelling, endoplasmatic reticulum dilatation and a decrease in glycogen granules. Furthermore, hepatocellular apoptosis and syncytialization were observed. 17 However, in contrast to the histopathological findings, these two cases did not fulfil the clinical criteria of acute liver failure. Furthermore, the observed changes may be seen during multi-organ dysfunction associated with critical illness, drug-induced liver injury and fatty liver disease, as described in. 18 It was also suggested that the spiked, 'coronalike' inclusions may have been intrahepatic cholesterol crystals or 'crown-like' structures seen in patients with fatty liver disease. 18 In conclusion, SARS-CoV-2 may target cholangiocytes and hepatocytes through ACE2 but the extent of cytopathic damage and liver injury caused by this potential infection remains to be clarified. release of cytokines ("cytokine storm"), cytopenias, disseminated intravascular coagulation and multiple organ dysfunction (including the lungs and liver). Interleukin (IL)-6 signalling plays a central role in the pathophysiology of cytokine-driven hyperinflammatory syndromes. 20 In a study from Austria, serum IL-6 levels were strongly correlated with elevated ASAT levels and peak ASAT and ALAT elevation in 96 hospitalized patients with COVID-19. 22 because only 1.6% of the patients had mild and 1.8% moderate or severe pre-existing liver conditions, while chronic cardiac disease, diabetes and obesity were found in 30.9%, 28.1% and 10.5% respectively. 32 However, the increased risk of a fatal outcome of COVID-19 in patients with pre-existing liver disease was confirmed in a large survey including more than 17 million cases. Chronic liver disease resulted in a hazard ratio of 1.75 for COVID-19-related death (95% confidence interval 1.15-2.03). 33 Liver function tests were not assessed in either study. A closer look at specific patient groups is interesting:

Individuals with a poorer prognosis of COVID-19 are typically older (>60) with metabolic co-morbidities such as obesity (body mass index >30 kg/m 2 ) and diabetes, a profile which is similar to those at increased risk of NAFLD. 33 Patients with NAFLD had a higher risk of progression to severe COVID-19 (45% vs 7%, P < .0001), a longer viral shedding time (17.5 ± 5.2 days vs 12.1 ± 4.4 days, P < .0001) and a higher likelihood of abnormal liver function tests from admission to discharge (70% vs 11.1%, P < .0001) compared to those without NAFLD. 35 Almost all liver injury was mild with a hepatocellular pattern.

Another study from China reported a >2-fold higher prevalence of severe COVID-19 in patients with NAFLD compared to those without NAFLD but only when they were under 60 years old and even after adjustment for possibly confounding factors such as being overweight, diabetes and hypertension (odds ratio 2.67, P = .03). In contrast, NAFLD was not associated with the severity of COVID-19 in elderly patients (> 60 years old). 36 The authors suggest that hepatic and systemic immune responses caused by NAFLD could increase the severity of the cytokine storm in younger patients with COVID-19. In the elderly, other comorbidities such as chronic cardiac disease are more prevalent and any association with NAFLD might be masked by influence of the former. 36 Obesity is characterized by low-grade chronic inflammation with increased serum levels of pro-inflammatory cyokines such as IL-6 (which can favour macrophage activation and development of the cytokine storm in COVID- 19) , and a specific immune dysfunction with impaired secretion of antiviral type I interferons (which probably increases the susceptibility to respiratory viral infections such as COVID-19). 37 The adipose tissue of obese patients is thought to express high levels of ACE2 and, thus potentially functions as SARS-CoV-2 reservoir with prolonged viral shedding time. 37 SARS-CoV-2 infection and the related hyperinflammatory syndrome could act as "second hit" to a simple fatty liver and trigger "acute-on-chronic" steatohepatitis (NASH) with elevated aminotransferases. 34 Moreover, hepatic expression of ACE2 was strongly upregulated in a high-fat diet-induced NASH model in rodents, 16 possibly increasing hepatic susceptibility to SARS-CoV-2 infection in patients with NAFLD or NASH. However, the association of NAFLD and hepatic expression of SARS-CoV-2 critical entry proteins, such as ACE2 and TMPRSS2, a host cell serine protease which cleaves the SARS-CoV-2 spike protein and mediates fusion of host cellular and viral membranes, are controversial.

No upregulation was found in a microarray data set comparing 12 lean and 16 obese patients without NAFLD with 9 patients with simple steatosis and 17 patients with biopsy-proven NASH. 38 In contrast, hepatic mRNA expression of ACE2 and TMPRSS2 was low in obese subjects without liver injury (n = 17) or with simple steatosis (n = 57) but significantly increased in obese patients with NASH (P < .01 and P < .05) and correlated with the NAFLD activity score (NAS) (P = .017 and P = .003, respectively). 39 Finally, obesity is related to hypercoagulation, mainly as a result of higher plasma concentrations of prothrombotic factors such as factor VII, fibrinogen and von Willebrand factor. This probably fosters microvascular thrombosis formation with ischemia-induced hypoxic liver damage. 37 In conclusion, an inherent immune activation and a tendency towards hypercoagulation are potential causes of the poorer prognosis of COVID-19 and a higher risk of abnormal liver function tests during the course of COVID-19 in patients with obesity and NAFLD.

Pre-existing cirrhosis with cirrhosis-associated immune dysfunction and immunosuppressive therapy after liver transplantation could fa- Overall mortality was 32% in patients with cirrhosis and 8% in those without (P < .001). The stage of liver disease was the most important determinant of outcome because mortality in patients with cirrhosis increased according to CTP class (A 19%, B 35% and C 51%) (Figure 3 ).

Fifty-five per cent of patients with cirrhosis developed one or more acute-on-chronic liver failure (ACLF) criteria, defined by the Clif consortium. 41 Mortality in patients with ACLF was higher than in those without (46% vs 14%, P < .001). Respiratory failure was the most common cause of death (71%), even in patients with ALCF. Alcohol-related liver disease was the only aetiology that was an independent risk factor of death from COVID-19 (odds ratio 3.11, P < .001). 42 Ninety-nine per cent of the patients in the LT cohort were taking immunosuppressive drugs when SARS-CoV-2 infection was diagnosed: tacrolimus (84%), prednisolone (44%), mycophenolate (51%), azathioprine (9%), cyclosporin (5%) and sirolimus (5%). The median time from liver transplantation was 5 years. The groups did not differ for hospitalization (82% vs 76%, P = .106) or the need for intensive care (31% vs 30%, P = .837). The percentage of patients who died in the LT cohort was lower than that in the non-LT cohort (19% vs 27%, P = .046). The main cause of death in both groups was respiratory failure (75% and 89%). The biological age (odds ratio 1.06 per 1 year increase, P = .031) but not the time since LT or immunosuppressive medication was associated with mortality in the LT cohort. The LT and non-LT cohorts did not differ in the frequency of mild liver injury (ALAT > 40 IU/L, 30% vs 28%, P = .734), moderate liver injury (ALAT > 80 IU/L, 16% vs 14%, P = .662) or severe liver injury (ALAT > 200 IU/L, 8% vs 4%, P = .052). 43 However, it is important to note that the median time from LT was 5 years, thus these results cannot be applied to patients who acquire SARS-CoV-2 infection in the perioperative period. 44 In a study from Spain, the inflammatory response after SARS-CoV-2 infection in solid organ transplant recipients (kidney, lung, liver, n = 46) and a matched control group (n = 166) was analysed. The inflammatory response in solid organ transplant recipients with COVID-19 was not stronger (according to lymphocyte count, IL-6 and CRP) than in the control group. In contrast, median IL-6 after 7 days of admission (231.4 vs 534.6 pg/ml, P = .433) and the incidence of acute respiratory distress syndrome (ARDS) (19.6% vs 27.1%, P = .06) were lower in transplant recipients than in the control group. 45 The authors suggest that immunosuppressive medication in solid organ transplant recipients might limit the inflammatory response and protect these patients from hyperinflammation and ARDS development in COVID-19.

Unlike the COVID-Hep registry study, 43 this study also included patients with a shorter time after transplantation (<3 months 6.7%, 3-6 months 6.7% and >12 months 87%). 45 In conclusion, although a reporting bias may have affected the COVID-Hep registry data, the overall evidence clearly suggests that cirrhosis strongly increases the risk of COVID-19-related liver injury and mortality with a positive correlation with the stage of cirrhosis. When hepatic function is restored by LT, the risk of liver injury and mortality return to that of the general population emphasizing the close association between chronic liver disease and an adverse outcome of COVID-19. 42 Clear data on the outcome of COVID-19 and post-operative transplant engraftment (<6 months) are lacking.

Studies on the influence of autoimmune liver diseases and chronic viral hepatitis without cirrhosis on COVID-19-related liver injury and outcome are limited. Reports from Northern Italy, China and Belgium suggest that the case-to-infection ratio is not higher in patients with autoimmune hepatitis (AIH), primary biliary cholangitis (PBC) or primary sclerosing cholangitis (PSC) without cirrhosis with a fairly favourable outcome for SARS-CoV-2 infection in these patients. 1, 46, 47 In a case series in 10 hospitalized patients with AIH and symptomatic SARS-CoV-2 infection, liver function tests remained normal throughout the hospital stay with a stable immunosuppression regimen, and improved in 2 cases with the onset of acute AIH and high-dose steroid induction therapy. 48 The authors concluded that reduction in immuno- This analysis shows that COVID-19 extends the direct morbidity and mortality associated with exposure and infection. 50 In conclusion, autoimmune liver diseases without cirrhosis do not seem to increase the risk of COVID-19-related liver injury and mortality, even though the number of patients evaluated is small. The influence of chronic viral hepatitis on liver function tests and the severity of COVID-19 remains to be clarified.

Although evidence is limited to hospitalized patients, abnormal liver function tests in COVID-19 are common, especially in patients with severe disease. This probably reflects multifactorial mechanisms of F I G U R E 3 Acute hepatic decompensation and fatality rates in hospitalized patients with chronic liver disease and COVID-19. Decompensation included new or worsening ascites (28%), hepatic encephalopathy (27%), spontaneous bacterial peritonitis (3%) and variceal haemorrhage (3%). CTP, Child-Turcotte-Pugh. Adapted from Ref. [42] [Correction added on 5 August 2021, after first online publication: Figure 3 image has been replaced.] liver injury. Initial abnormalities include elevated aminotransferases, probably mainly because of hypoxic hepatocellular damage. The tropism of SARS-CoV-2 is broad and includes hepatocytes and cholangiocytes. Nevertheless, cases of acute hepatitis are rare. A delayed cholestatic liver biochemistry pattern can develop in patients with critical COVID-19, and its close association with inflammatory response markers supports underlying cytokine-induced molecular mechanisms. Well-controlled pre-existing chronic liver disease without cirrhosis is not associated with a risk of abnormal liver function tests or a fatal outcome, except in patients with pre-existing NAFLD, who have a higher risk of progression to severe COVID-19 and likelihood of abnormal liver function tests. Cirrhosis strongly increases the risk of COVID-19-related liver injury and mortality, with a clear positive correlation with the stage of cirrhosis. The SARS-CoV-2 infection-related risk of liver injury and mortality is similar to that of the general population following liver transplantation, although more data on its effect in the early postoperative period are needed.

Optimal treatment and compensation of chronic liver diseases are highly important in this period of limited healthcare resources to prevent severe courses of COVID-19 in these patients. 51, 52 com.

The authors declare no conflict of interest with regard to this work.

https://orcid.org/0000-0003-0003-6241

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Liver injury during highly pathogenic human coronavirus infections

Manifestations and prognosis of gastrointestinal and liver involvement in patients with COVID-19: a systematic review and meta-analysis

Liver biochemistries in hospitalized patients with COVID-19

Clinical characteristics of Coronavirus disease 2019 in China

COVID-19: abnormal liver function tests

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

COVID-19 and liver dysfunction: current insights and emergent therapeutic strategies

SARS-CoV-2 infection induces a dual response in liver function tests: association with mortality during hospitalization

Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses

Specific ACE2 expression in cholangiocytes may cause liver damage after 2019-nCoV infection

Comparative tropism, replication kinetics, and cell damage profiling of SARS-CoV-2 and SARS-CoV with implications for clinical manifestations, transmissibility, and laboratory studies of COVID-19: an observational study

A human pluripotent stem cell-based platform to study SARS-CoV-2 tropism and model virus infection in human cells and organoids

Histopathological findings and viral tropism in UK patients with severe fatal COVID-19: a postmortem study

Chronic liver injury in rats and humans upregulates the novel enzyme angiotensin converting enzyme 2

Pioglitazone upregulates hepatic angiotensin converting enzyme 2 expression in rats with steatohepatitis

SARS-CoV-2 infection of the liver directly contributes to hepatic impairment in patients with COVID-19

SARS-CoV-2 related liver impairment -perception may not be the reality

Complex immune dysregulation in COVID-19 patients with severe respiratory failure

Cytokine release syndrome in severe COVID-19

COVID-19: consider cytokine storm syndromes and immunosuppression

Systemic inflammation as fuel for acute liver injury in COVID-19

Cytokine-dependent bystander hepatitis due to intrahepatic murine CD8+ T-cell activation by bone marrow-derived cells

Characteristics and mechanism of liver injury in 2019 Coronavirus disease

Clinical characteristics of COVID-19 patients with abnormal liver tests

Liver and COVID 19 infection: a very preliminary lesson learnt from histological postmortem findings in 48 patients

Coagulopathy in COVID-19

Endothelial cell infection and endotheliitis in COVID-19

COVID-19-associated vasculitis and vasculopathy

A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19

Clinical characteristics and outcomes of coronavirus disease 2019 among patients with preexisting liver disease in the United States: a multicenter research network study

Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study

Factors associated with COVID-19-related death using OpenSAFELY

COVID-19 and hepatic involvement: the liver as a main actor of the pandemic novel

Non-alcoholic fatty liver diseases in patients with COVID-19: a retrospective study

Younger patients with MAFLD are at increased risk of severe COVID-19 illness: a multicenter preliminary analysis

Hypercoagulopathy and adipose tissue exacerbated inflammation may explain higher mortality in COVID-19 patients with obesity

No evidence for an increased liver uptake of SARS-CoV-2 in metabolic-associated fatty liver disease

Obese patients with NASH have increased hepatic expression of SARS-CoV-2 critical entry points

High rates of 30-day mortality in patients with cirrhosis and COVID-19

Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis

Outcomes following SARS-CoV-2 infection in patients with chronic liver disease: an international registry study

Outcomes following SARS-CoV-2 infection in liver transplant recipients: an international registry study

SARS-CoV-2 infection in liver transplant recipients: collaboration in the time of COVID-19

COVID-19 in solid organ transplantation: a matched retrospective cohort study and evaluation of immunosuppression management

Health status of patients with autoimmune hepatitis is not affected by the SARS-CoV-2 outbreak in Flanders

Health status of patients with autoimmune liver disease during SARS-CoV-2 outbreak in northern Italy

Coronavirus Disease 2019 (COVID-19) in autoimmune hepatitis: a lesson from immunosuppressed patients

Low risk of hepatitis b reactivation in patients with severe COVID-19 who receive immunosuppressive therapy

Impact of COVID-19 on global hepatitis C elimination efforts

Care of patients with liver disease during the COVID-19 pandemic: EASL-ESCMID position paper

Impact of COVID-19 on the care of patients with liver disease: EASL-ESCMID position paper after 6 months of the pandemic